» Articles » PMID: 15262102

The Cervical Cancer Epidemic That Screening Has Prevented in the UK

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 2004 Jul 21
PMID 15262102
Citations 216
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Recent reports suggest that the reduction in mortality achieved by the UK national cervical screening programme is too small to justify its financial and psychosocial costs, except perhaps in a few high-risk women.

Methods: We analysed trends in mortality before 1988, when the British national screening programme was launched, to estimate what future trends in cervical cancer mortality would have been without any screening.

Findings: Cervical cancer mortality in England and Wales in women younger than 35 years rose three-fold from 1967 to 1987. By 1988, incidence in this age-range was among the highest in the world despite substantial opportunistic screening. Since national screening was started in 1988, this rising trend has been reversed.

Interpretation: Cervical screening has prevented an epidemic that would have killed about one in 65 of all British women born since 1950 and culminated in about 6000 deaths per year in this country. However, these estimates are subject to substantial uncertainty, particularly in relation to the effects of oral contraceptives and changes in sexual behaviour. 80% or more of these deaths (up to 5000 deaths per year) are likely to be prevented by screening, which means that about 100000 (one in 80) of the 8 million British women born between 1951 and 1970 will be saved from premature death by the cervical screening programme at a cost per life saved of about pound 36000. The birth cohort trends also provide strong evidence that the death rate throughout life is substantially lower in women who were first screened when they were younger.

Citing Articles

Short term complications of conisation and long term effects on fertility related outcomes in Denmark: register based nationwide cohort study.

Aagaard M, Rogvi J, Modin F, Nicolaisdottir D, Siersma V, Brandt Brodersen J BMJ. 2025; 388():e078140.

PMID: 39814419 PMC: 11733743. DOI: 10.1136/bmj-2023-078140.


A Clinical Prediction Model for Pathologic Upgrade to Invasive Carcinoma Following Conization of Cervical High-Grade Squamous Intraepithelial Lesions.

Liu Q, Yang J, Cheng H, Shu C, Tang Y, Zhao J Cancer Med. 2024; 14(1):e70540.

PMID: 39739926 PMC: 11683552. DOI: 10.1002/cam4.70540.


Hiporfin-photodynamic therapy for high-grade squamous intraepithelial lesions of the endocervical canal in young women.

Liu Y, Li R, Li C, Shang J, Wei L, Wu R Sci Rep. 2024; 14(1):28423.

PMID: 39558016 PMC: 11574053. DOI: 10.1038/s41598-024-79980-1.


Cervical cancer screening: efficacy of PAX1 and JAM3 methylation assay in the triage of atypical squamous cell of undetermined significance (ASC-US).

Chen X, Jiang H, Xu H, Wang L, Liu P, Ma D BMC Cancer. 2024; 24(1):1385.

PMID: 39528979 PMC: 11556146. DOI: 10.1186/s12885-024-13082-z.


Photodynamic therapy compared with loop electrosurgical excision procedure in patients with cervical high-grade squamous intraepithelial lesion.

Liu Y, Li R, Li C, Liu Z, Duan L, Huang Q Sci Rep. 2024; 14(1):27090.

PMID: 39511389 PMC: 11543842. DOI: 10.1038/s41598-024-78445-9.